Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel Free NTLA Stock Alerts

Intellia Therapeutics (NTLA) Financials

Intellia Therapeutics logo
$14.09 +0.38 (+2.77%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$14.17 +0.08 (+0.60%)
As of 05/8/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Intellia Therapeutics

Annual Income Statements for Intellia Therapeutics

This table shows Intellia Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -12 -32 -68 -85 -100 -134 -268 -474 -481 -519 -413
Consolidated Net Income / (Loss)		 -12 -32 -68 -85 -100 -134 -268 -474 -481 -519 -413
Net Income / (Loss) Continuing Operations		 -12 -32 -68 -85 -99 -134 -270 -474 -477 -518 -412
Total Pre-Tax Income 		-13 -32 -68 -85 -99 -134 -270 -474 -477 -518 -412
Total Operating Income		 -13 -32 -70 -91 -106 -137 -268 -458 -515 -534 -441
Total Gross Profit		 6.04 16 26 30 43 58 33 52 36 58 68
Total Revenue		 6.04 16 26 30 43 58 33 52 36 58 68
Operating Revenue		 6.04 16 26 30 43 58 33 52 36 58 68
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 19 49 96 121 149 195 301 510 552 592 509
Selling, General & Admin Expense		 8.28 17 28 32 41 44 71 90 116 126 120
Research & Development Expense		 11 32 68 89 108 150 230 420 435 466 389
Other Special Charges / (Income)		 - - - - - 0.00 0.00 - 0.10 0.00 0.00
Total Other Income / (Expense), net		 0.00 0.53 2.01 5.50 7.12 2.35 -2.21 -16 38 16 29
Interest & Investment Income		 0.00 0.53 2.01 5.53 6.84 2.35 -0.04 -2.54 34 15 28
Other Income / (Expense), net		 - 0.00 0.00 -0.03 0.29 0.00 -2.17 -13 3.64 0.73 0.43
Basic Earnings per Share		 ($51.02) ($1.42) ($1.88) ($1.98) ($2.11) ($2.40) ($3.78) ($6.16) ($5.42) ($5.25) ($3.81)
Weighted Average Basic Shares Outstanding		 243K 22.22M 36.01M 43.07M 47.25M 55.99M 70.89M 76.97M 88.77M 98.85M 108.38M
Diluted Earnings per Share		 ($51.02) ($1.42) ($1.88) ($1.98) ($2.11) ($2.40) ($3.78) ($6.16) ($5.42) ($5.25) ($3.81)
Weighted Average Diluted Shares Outstanding		 243K 22.22M 36.01M 43.07M 47.25M 55.99M 70.89M 76.97M 88.77M 98.85M 108.38M
Weighted Average Basic & Diluted Shares Outstanding		 243K 22.22M 36.01M 43.07M 47.25M 55.99M 70.89M 88.02M 96.11M 103.52M 118.13M

Quarterly Income Statements for Intellia Therapeutics

This table shows Intellia Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -124 -122 -132 -107 -147 -136 -129 -114 -101 -101 -96
Consolidated Net Income / (Loss)		 -124 -122 -132 -107 -147 -136 -129 -114 -101 -101 -96
Net Income / (Loss) Continuing Operations		 -125 -122 -128 -108 -147 -136 -128 -114 -102 -101 -96
Total Pre-Tax Income 		-125 -122 -128 -108 -147 -136 -128 -114 -102 -101 -96
Total Operating Income		 -132 -131 -140 -114 -139 -145 -136 -121 -110 -111 -99
Total Gross Profit		 14 12 -1.92 29 6.96 9.11 13 17 14 14 23
Total Revenue		 14 12 -1.92 29 6.96 9.11 13 17 14 14 23
Operating Revenue		 14 12 -1.92 29 6.96 9.11 13 17 14 14 23
Total Operating Expenses		 146 143 138 143 146 154 149 137 124 125 122
Selling, General & Admin Expense		 31 29 29 31 32 31 32 29 27 31 33
Research & Development Expense		 115 114 109 112 114 123 117 108 97 95 89
Total Other Income / (Expense), net		 7.46 9.18 12 5.75 -8.14 9.06 8.49 6.93 8.34 10 2.97
Interest & Investment Income		 8.65 8.88 7.73 6.57 -7.93 9.06 7.55 6.48 8.74 10 2.92
Other Income / (Expense), net		 -1.19 0.30 4.63 -0.82 -0.21 - 0.94 0.45 -0.40 0.34 0.04
Basic Earnings per Share		 ($1.40) ($1.38) ($1.47) ($1.12) ($1.52) ($1.34) ($1.27) ($1.10) ($0.98) ($0.92) ($0.81)
Weighted Average Basic Shares Outstanding		 88.19M 88.65M 88.77M 95.50M 96.98M 101.00M 98.85M 103.50M 103.73M 110.19M 108.38M
Diluted Earnings per Share		 ($1.40) ($1.38) ($1.47) ($1.12) ($1.52) ($1.34) ($1.27) ($1.10) ($0.98) ($0.92) ($0.81)
Weighted Average Diluted Shares Outstanding		 88.19M 88.65M 88.77M 95.50M 96.98M 101.00M 98.85M 103.50M 103.73M 110.19M 108.38M
Weighted Average Basic & Diluted Shares Outstanding		 88.49M 89.55M 96.11M 96.48M 101.58M 101.85M 103.52M 103.58M 107.35M 115.83M 118.13M

Annual Cash Flow Statements for Intellia Therapeutics

This table details how cash moves in and out of Intellia Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 66 197 68 -282 5.82 107 -39 410 -295 -38 -35
Net Cash From Operating Activities		 -1.76 36 -65 -61 -103 -50 -225 -333 -394 -349 -395
Net Cash From Continuing Operating Activities		 -1.76 36 -65 -61 -96 -50 -225 -333 -394 -349 -395
Net Income / (Loss) Continuing Operations		 -12 -32 -68 -85 -100 -134 -268 -474 -481 -519 -413
Consolidated Net Income / (Loss)		 -12 -32 -68 -85 -100 -134 -268 -474 -481 -519 -413
Depreciation Expense		 0.33 1.10 2.99 4.46 5.59 6.31 6.89 7.57 8.98 10 9.77
Amortization Expense		 - 0.00 0.00 -0.68 3.73 0.54 7.60 4.00 -26 -18 0.30
Non-Cash Adjustments To Reconcile Net Income		 1.32 6.73 15 17 21 26 61 183 175 187 115
Changes in Operating Assets and Liabilities, net		 8.99 60 -16 3.18 -26 51 -32 -54 -71 -9.59 -107
Net Cash From Investing Activities		 -2.55 -6.17 -10 -261 25 -214 -551 160 -31 126 228
Net Cash From Continuing Investing Activities		 -2.55 -6.17 -10 -261 25 -214 -551 160 -31 126 228
Purchase of Property, Plant & Equipment		 -2.55 -6.17 -10 -6.36 -6.79 -3.59 -13 -14 -14 -5.78 -1.13
Acquisitions		 - - - - - - 0.00 -45 0.00 0.00 0.00
Purchase of Investments		 - 0.00 0.00 -255 -297 -474 -1,021 -429 -904 -936 -323
Sale of Property, Plant & Equipment		 - 0.00 0.00 0.13 0.00 0.00 0.00 0.15 0.00 0.00 0.00
Sale and/or Maturity of Investments		 - - 0.00 0.00 329 263 486 648 887 1,067 552
Net Cash From Financing Activities		 70 167 143 40 76 372 737 583 130 186 131
Net Cash From Continuing Financing Activities		 70 167 143 40 76 372 737 583 130 186 131
Issuance of Common Equity		 0.00 171 142 30 73 360 696 568 124 180 131
Other Financing Activities, net		 -1.10 -0.60 1.16 11 3.09 12 41 15 6.60 5.86 0.72

Quarterly Cash Flow Statements for Intellia Therapeutics

This table details how cash moves in and out of Intellia Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Change in Cash & Equivalents		 -122 -2.78 59 -55 -41 -10 69 -55 22 37 -40
Net Cash From Operating Activities		 -90 -101 -93 -121 -58 -85 -85 -149 -100 -77 -69
Net Cash From Continuing Operating Activities		 -90 -101 -93 -121 -58 -85 -85 -149 -100 -77 -69
Net Income / (Loss) Continuing Operations		 -124 -122 -132 -107 -147 -136 -129 -114 -101 -101 -96
Consolidated Net Income / (Loss)		 -124 -122 -132 -107 -147 -136 -129 -114 -101 -101 -96
Depreciation Expense		 2.17 2.29 2.47 2.51 2.60 2.61 2.57 2.50 2.47 2.42 2.38
Amortization Expense		 -7.10 -7.92 -6.31 -5.29 -4.65 -4.28 -3.60 -2.28 -1.67 1.44 2.81
Non-Cash Adjustments To Reconcile Net Income		 48 45 45 24 66 48 49 31 30 25 29
Changes in Operating Assets and Liabilities, net		 -9.69 -18 -1.75 -35 25 4.86 -4.38 -66 -29 -4.23 -7.80
Net Cash From Investing Activities		 -35 80 46 5.90 -24 -7.71 152 94 107 -0.74 28
Net Cash From Continuing Investing Activities		 -35 80 46 5.90 -24 -7.71 152 94 107 -0.74 28
Purchase of Property, Plant & Equipment		 -4.30 -4.33 -1.52 -2.51 -1.01 -1.28 -0.98 -0.74 -0.24 -0.03 -0.13
Purchase of Investments		 -243 -129 -150 -260 -301 -206 -169 -83 -56 -117 -67
Sale and/or Maturity of Investments		 213 213 197 268 278 200 322 178 163 116 95
Net Cash From Financing Activities		 2.52 19 106 60 41 82 2.32 0.00 15 115 1.98
Net Cash From Continuing Financing Activities		 2.52 19 106 60 41 82 2.32 0.00 15 115 1.98
Issuance of Common Equity		 2.05 15 105 58 40 80 1.29 0.00 15 115 1.35
Other Financing Activities, net		 0.47 4.38 1.00 1.96 1.18 1.70 1.03 0.00 - 0.10 0.63

Annual Balance Sheets for Intellia Therapeutics

This table presents Intellia Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 82 299 376 347 334 676 1,294 1,520 1,301 1,191 842
Total Current Assets		 78 281 355 325 289 617 769 1,217 998 640 528
Cash & Equivalents		 76 273 341 59 57 160 123 524 227 189 155
Short-Term Investments		 - - 0.00 255 223 437 625 669 685 412 294
Accounts Receivable		 1.00 6.45 10 7.55 4.62 2.13 2.03 3.77 36 8.52 9.47
Prepaid Expenses		 0.81 1.79 3.68 3.37 5.14 17 19 20 50 30 68
Plant, Property, & Equipment, net		 2.71 11 15 17 18 16 21 28 33 27 18
Total Noncurrent Assets		 1.81 7.04 6.13 5.28 27 44 504 275 270 524 297
Long-Term Investments		 - - - 0.00 4.75 4.75 425 142 155 304 191
Other Noncurrent Operating Assets		 1.81 7.04 6.13 5.28 22 39 79 133 115 219 106
Total Liabilities & Shareholders' Equity		 82 299 376 347 334 676 1,294 1,520 1,301 1,191 842
Total Liabilities		 15 89 76 69 64 149 254 285 251 319 171
Total Current Liabilities		 11 31 31 41 36 64 126 127 115 111 104
Accounts Payable		 1.36 4.65 2.17 2.71 3.94 10 9.65 5.15 7.45 15 20
Accrued Expenses		 2.79 5.90 8.00 11 13 26 43 61 67 55 50
Current Deferred Revenue		 6.55 20 21 27 13 23 64 44 22 21 7.29
Other Current Liabilities		 - - - 0.00 5.75 5.70 9.11 17 19 20 26
Total Noncurrent Liabilities		 4.09 58 44 29 29 85 128 158 136 208 67
Noncurrent Deferred Revenue		 3.77 58 44 29 16 51 63 20 39 18 0.00
Other Noncurrent Operating Liabilities		 0.32 0.29 0.17 0.01 13 34 65 138 97 190 67
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -21 210 301 278 270 527 1,040 1,236 1,050 872 671
Total Preferred & Common Equity		 -21 210 301 278 270 527 1,040 1,236 1,050 872 671
Total Common Equity		 -21 210 301 278 270 527 1,040 1,236 1,050 872 671
Common Stock		 0.74 263 422 479 570 962 1,746 2,420 2,711 3,049 3,260
Retained Earnings		 -22 -54 -121 -201 -301 -435 -703 -1,177 -1,658 -2,177 -2,590
Accumulated Other Comprehensive Income / (Loss)		 - - 0.00 -0.03 0.26 0.00 -2.63 -7.46 -2.26 0.61 1.03

Quarterly Balance Sheets for Intellia Therapeutics

This table presents Intellia Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 6/30/2022 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025
Total Assets		 1,110 1,084 1,418 1,323 1,243 1,260 1,192 1,173 986 899 925
Total Current Assets		 895 859 964 940 893 884 757 711 551 496 582
Cash & Equivalents		 148 141 294 172 168 172 131 120 127 156 193
Short-Term Investments		 726 687 639 736 687 619 560 538 377 303 318
Accounts Receivable		 2.85 4.02 4.91 5.06 6.49 36 12 8.85 11 11 11
Prepaid Expenses		 18 27 25 26 32 56 54 44 37 25 60
Plant, Property, & Equipment, net		 26 27 32 33 34 32 30 29 25 23 20
Total Noncurrent Assets		 189 199 423 350 316 343 404 434 410 380 323
Long-Term Investments		 115 98 294 227 197 233 299 333 272 251 205
Other Noncurrent Operating Assets		 74 101 128 124 119 110 105 100 138 129 118
Total Liabilities & Shareholders' Equity		 1,110 1,084 1,418 1,323 1,243 1,260 1,192 1,173 986 899 925
Total Liabilities		 230 260 227 218 206 223 220 211 206 184 177
Total Current Liabilities		 124 131 103 100 92 98 105 106 113 95 94
Accounts Payable		 7.52 4.38 6.89 12 3.55 14 19 13 12 9.80 13
Accrued Expenses		 45 58 45 50 58 43 45 51 41 42 41
Current Deferred Revenue		 62 55 35 22 13 22 22 22 21 17 12
Other Current Liabilities		 9.57 14 16 17 17 19 19 19 39 27 27
Total Noncurrent Liabilities		 106 128 124 119 114 126 115 105 94 88 83
Noncurrent Deferred Revenue		 35 26 14 13 13 33 28 23 13 13 13
Other Noncurrent Operating Liabilities		 71 103 110 106 101 92 87 82 80 76 71
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 881 825 1,191 1,105 1,037 1,036 971 963 780 715 748
Total Preferred & Common Equity		 881 825 1,191 1,105 1,037 1,036 971 963 780 715 748
Total Common Equity		 881 825 1,191 1,105 1,037 1,036 971 963 780 715 748
Common Stock		 1,841 1,898 2,474 2,513 2,567 2,803 2,885 3,008 3,071 3,108 3,242
Retained Earnings		 -951 -1,064 -1,280 -1,404 -1,526 -1,766 -1,913 -2,049 -2,292 -2,393 -2,494
Accumulated Other Comprehensive Income / (Loss)		 -9.55 -9.37 -2.68 -3.87 -3.57 -0.95 -1.16 3.30 1.06 0.65 0.99

Annual Metrics And Ratios for Intellia Therapeutics

This table displays calculated financial ratios and metrics derived from Intellia Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - - - - - 115,829,926.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 115,829,926.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -3.56
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 172.65% 58.49% 16.53% 41.63% 34.55% -43.01% 57.69% -30.40% 59.55% 16.92%
EBITDA Growth		 0.00% -137.41% -114.33% -30.87% -11.09% -34.07% -96.96% -80.05% -14.89% -2.36% 20.43%
EBIT Growth		 0.00% -139.83% -116.28% -30.69% -16.70% -28.76% -97.70% -74.67% -8.48% -4.28% 17.43%
NOPAT Growth		 0.00% -139.83% -116.28% -30.64% -17.06% -28.41% -96.11% -71.05% -12.47% -3.68% 17.46%
Net Income Growth		 0.00% -155.17% -113.51% -26.35% -16.63% -34.86% -99.58% -77.01% -1.48% -7.86% 20.49%
EPS Growth		 0.00% 97.22% -32.39% -5.32% -6.57% -13.74% -57.50% -62.96% 12.01% 3.14% 27.43%
Operating Cash Flow Growth		 0.00% 2,148.16% -280.77% 6.16% -68.54% 51.65% -350.85% -48.11% -18.24% 11.47% -13.14%
Free Cash Flow Firm Growth		 0.00% 0.00% -322.70% 5.96% -42.12% 63.39% -267.11% -174.98% -24.98% 19.61% -4.75%
Invested Capital Growth		 0.00% -647.36% 36.61% 9.84% 59.63% -414.34% -77.88% 25.57% 83.33% -105.47% 190.25%
Revenue Q/Q Growth		 0.00% 31.36% 4.15% 4.15% 7.63% -6.96% 23.36% 1.40% -29.92% 34.33% 17.63%
EBITDA Q/Q Growth		 0.00% -19.46% -25.36% 4.03% -1.08% -16.71% -17.81% -8.40% -4.96% 0.85% 9.35%
EBIT Q/Q Growth		 0.00% -19.87% -24.96% 4.16% -9.35% -9.92% -17.81% -7.26% -4.14% 0.34% 7.97%
NOPAT Q/Q Growth		 0.00% -19.87% -24.96% 4.19% -9.27% -10.19% -16.54% -6.92% -6.14% 0.64% 7.88%
Net Income Q/Q Growth		 0.00% -20.21% -24.75% 5.43% -10.20% -11.57% -17.06% -7.28% -4.06% 0.62% 7.43%
EPS Q/Q Growth		 0.00% 97.04% -124.10% 9.59% -7.65% -5.26% -12.50% -4.58% -1.69% 3.67% 10.77%
Operating Cash Flow Q/Q Growth		 0.00% -19.81% -11.81% 17.25% -24.21% -30.16% -6.85% -11.82% -0.81% 2.20% 3.87%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -10.45% 18.44% -4.22% -143.48% 4.23% -16.91% -4.09% 1.57% 5.77%
Invested Capital Q/Q Growth		 0.00% 12.78% 13.65% -20.55% -143.35% 4.19% -27.80% 1.50% -13.04% -17.97% -5.03%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -216.43% -188.45% -254.86% -286.23% -224.50% -223.70% -773.07% -882.70% -1,457.14% -934.85% -636.16%
Operating Margin		 -221.86% -195.15% -266.32% -298.58% -246.78% -235.51% -810.37% -879.04% -1,420.51% -923.10% -651.67%
EBIT Margin		 -221.86% -195.15% -266.32% -298.67% -246.11% -235.51% -816.92% -904.91% -1,410.49% -921.84% -651.04%
Profit (Net Income) Margin		 -205.11% -191.97% -258.62% -280.42% -230.92% -231.46% -810.49% -909.78% -1,326.51% -896.77% -609.85%
Tax Burden Percent		 92.45% 100.00% 100.00% 99.97% 100.29% 100.00% 99.20% 100.00% 100.78% 100.14% 100.10%
Interest Burden Percent		 100.00% 98.37% 97.11% 93.92% 93.56% 98.28% 100.02% 100.54% 93.32% 97.14% 93.58%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -18.41% -22.82% -26.46% -29.50% -36.34% -33.69% -34.18% -41.67% -42.10% -54.00% -53.48%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,215.66%
Operating Return on Assets (OROA)		 -16.32% -16.88% -20.60% -25.13% -31.13% -27.03% -27.40% -33.51% -36.27% -42.82% -43.34%
Return on Assets (ROA)		 -15.09% -16.60% -20.01% -23.59% -29.21% -26.56% -27.19% -33.70% -34.11% -41.66% -40.60%
Return on Common Equity (ROCE)		 5.79% -15.53% -26.46% -29.50% -36.34% -33.69% -34.18% -41.67% -42.10% -54.00% -53.48%
Return on Equity Simple (ROE_SIMPLE)		 58.47% -15.08% -22.47% -30.71% -36.88% -25.47% -25.75% -38.38% -45.82% -59.52% 0.00%
Net Operating Profit after Tax (NOPAT)		 -9.39 -23 -49 -64 -74 -96 -187 -321 -361 -374 -309
NOPAT Margin		 -155.30% -136.61% -186.42% -209.01% -172.74% -164.86% -567.26% -615.33% -994.36% -646.17% -456.17%
Net Nonoperating Expense Percent (NNEP)		 -3.97% -5.23% -6.14% -6.64% -8.38% -8.71% -9.05% -12.24% -10.03% -14.70% -13.45%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -25.96% -34.35% -42.89% -45.98%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 137.05% 101.94% 107.31% 105.77% 95.26% 76.16% 215.10% 173.26% 321.15% 217.41% 177.03%
R&D to Revenue		 184.81% 193.22% 259.02% 292.81% 251.52% 259.35% 695.27% 805.78% 1,199.36% 805.69% 574.63%
Operating Expenses to Revenue		 321.86% 295.15% 366.32% 398.58% 346.78% 335.51% 910.37% 979.04% 1,520.79% 1,023.10% 751.67%
Earnings before Interest and Taxes (EBIT)		 -13 -32 -70 -91 -106 -137 -270 -472 -512 -534 -441
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -13 -31 -67 -87 -97 -130 -256 -460 -529 -541 -430
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 2.25 2.31 2.13 2.66 6.10 8.46 2.22 2.60 1.36 1.55
Price to Tangible Book Value (P/TBV)		 0.00 2.25 2.31 2.13 2.66 6.10 8.46 2.22 2.60 1.36 1.55
Price to Revenue (P/Rev)		 0.00 28.64 26.56 19.47 16.64 55.42 266.22 52.67 75.27 20.52 15.39
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 13.04
Enterprise Value to Revenue (EV/Rev)		 0.00 12.07 13.51 9.15 10.04 45.04 230.71 27.06 45.87 4.86 5.92
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 5.51 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 6.16 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.13 -1.26 -1.20 -1.13 -1.09 -1.11 -1.13 -1.10 -1.05 -1.03 -1.00
Leverage Ratio		 1.22 1.37 1.32 1.25 1.24 1.27 1.26 1.24 1.23 1.30 1.32
Compound Leverage Factor		 1.22 1.35 1.28 1.17 1.16 1.25 1.26 1.24 1.15 1.26 1.23
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 131.48% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -31.48% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 3.63 5.54 4.52 5.41 12.42 19.94 4.58 4.29 -1.22 -1.69
Noncontrolling Interest Sharing Ratio		 131.48% 31.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 7.26 9.15 11.32 8.01 8.12 9.60 6.11 9.61 8.67 5.77 5.08
Quick Ratio		 7.18 9.10 11.20 7.93 7.98 9.33 5.97 9.45 8.23 5.50 4.42
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 32 -72 -68 -96 -35 -129 -355 -443 -357 -373
Operating Cash Flow to CapEx		 -69.03% 585.71% -646.87% -983.73% -1,519.58% -1,392.25% -1,764.11% -2,485.73% -2,817.92% -6,038.08% -34,963.33%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.07 0.09 0.08 0.08 0.13 0.11 0.03 0.04 0.03 0.05 0.07
Accounts Receivable Turnover		 6.04 4.42 3.09 3.38 7.09 17.18 15.89 17.98 1.80 2.57 7.53
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 2.23 2.47 2.02 1.88 2.46 3.42 1.79 2.13 1.20 1.92 3.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 60.39 82.55 118.27 108.05 51.52 21.24 22.97 20.31 202.37 141.81 48.50
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 60.39 82.55 118.27 108.05 51.52 21.24 22.97 20.31 202.37 141.81 48.50
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -8.46 -63 -40 -36 -15 -75 -133 -99 -17 -34 31
Invested Capital Turnover		 -0.71 -0.46 -0.51 -0.80 -1.70 -1.29 -0.32 -0.45 -0.63 -2.29 -40.79
Increase / (Decrease) in Invested Capital		 0.00 -55 23 3.94 22 -60 -58 34 83 -17 65
Enterprise Value (EV)		 0.00 199 353 279 433 2,612 7,626 1,410 1,664 282 401
Market Capitalization		 0.00 472 694 593 717 3,214 8,799 2,745 2,731 1,188 1,041
Book Value per Share		 ($87.25) $5.83 $8.33 $6.40 $5.52 $8.92 $13.98 $15.70 $11.73 $8.56 $5.80
Tangible Book Value per Share		 ($87.25) $5.83 $8.33 $6.40 $5.52 $8.92 $13.98 $15.70 $11.73 $8.56 $5.80
Total Capital		 67 210 301 278 270 527 1,040 1,236 1,050 872 671
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -76 -273 -341 -314 -284 -602 -1,174 -1,335 -1,067 -906 -641
Capital Expenditures (CapEx)		 2.55 6.17 10 6.23 6.79 3.59 13 13 14 5.78 1.13
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -8.89 -22 -17 -30 -26 -45 -105 -102 -29 -73 -26
Debt-free Net Working Capital (DFNWC)		 67 251 323 284 254 552 643 1,090 883 529 424
Net Working Capital (NWC)		 67 251 323 284 254 552 643 1,090 883 529 424
Net Nonoperating Expense (NNE)		 3.01 9.12 19 22 25 39 80 153 120 145 104
Net Nonoperating Obligations (NNO)		 -76 -273 -341 -314 -284 -602 -1,174 -1,335 -1,067 -906 -641
Total Depreciation and Amortization (D&A)		 0.33 1.10 2.99 3.79 9.31 6.85 14 12 -17 -7.53 10
Debt-free, Cash-free Net Working Capital to Revenue		 -147.01% -136.46% -65.88% -97.44% -60.04% -77.78% -318.33% -196.43% -80.22% -125.27% -38.51%
Debt-free Net Working Capital to Revenue		 1,107.40% 1,520.58% 1,238.55% 934.50% 588.93% 952.28% 1,946.78% 2,091.75% 2,434.52% 914.03% 626.31%
Net Working Capital to Revenue		 1,107.40% 1,520.58% 1,238.55% 934.50% 588.93% 952.28% 1,946.78% 2,091.75% 2,434.52% 914.03% 626.31%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($3.78) ($6.16) ($5.42) ($5.25) ($3.81)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 0.00 0.00 0.00 74.67M 76.97M 88.77M 98.85M 108.38M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($3.78) ($6.16) ($5.42) ($5.25) ($3.81)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 0.00 0.00 0.00 74.67M 76.97M 88.77M 98.85M 108.38M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($3.78) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 0.00 0.00 0.00 70.89M 88.02M 96.11M 103.52M 118.13M
Normalized Net Operating Profit after Tax (NOPAT)		 -9.39 -23 -49 -64 -74 -96 -187 -321 -361 -374 -309
Normalized NOPAT Margin		 -155.30% -136.61% -186.42% -209.01% -172.74% -164.86% -567.26% -615.33% -994.17% -646.17% -456.17%
Pre Tax Income Margin		 -221.86% -191.97% -258.62% -280.51% -230.25% -231.46% -817.05% -909.78% -1,316.22% -895.50% -609.22%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -4.86% -8.74% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Intellia Therapeutics

This table displays calculated financial ratios and metrics derived from Intellia Therapeutics' official financial filings.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
DEI Shares Outstanding		 - - - - - - - - - - 115,829,926.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 115,829,926.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -0.83
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -3.11% -9.60% -114.12% 129.53% -48.82% -24.02% 771.57% -42.54% 104.76% 51.27% 78.79%
EBITDA Growth		 -45.70% -23.41% -21.89% -1.92% -2.06% -7.33% 1.84% -2.16% 22.44% 26.74% 32.01%
EBIT Growth		 -35.06% -15.41% -17.72% -1.74% -4.29% -10.67% -0.18% -4.82% 20.72% 23.23% 27.69%
NOPAT Growth		 -34.62% -24.24% -27.07% -1.83% -5.07% -10.42% 2.46% -5.97% 20.89% 23.00% 27.66%
Net Income Growth		 -22.85% -7.94% -16.54% -4.18% -18.83% -11.04% 2.47% -6.42% 31.11% 25.34% 25.69%
EPS Growth		 -5.26% 7.38% -6.52% 4.27% -8.57% 2.90% 13.61% 1.79% 35.53% 31.34% 36.22%
Operating Cash Flow Growth		 -6.15% -29.11% -3.54% -10.37% 35.58% 16.32% 8.45% -23.43% -71.21% 9.36% 18.67%
Free Cash Flow Firm Growth		 -959.35% -129.78% -62.52% 24.36% 36.64% 51.04% 56.82% 39.93% 7.91% -59.78% -71.52%
Invested Capital Growth		 72.43% 85.47% 83.33% 131.84% 37.99% -96.89% -105.47% -61.83% 124.17% 212.11% 190.25%
Revenue Q/Q Growth		 7.84% -11.78% -115.99% 1,609.39% -75.96% 30.96% 41.30% 29.15% -14.33% -3.25% 67.01%
EBITDA Q/Q Growth		 -20.83% 1.45% -1.95% 17.20% -21.00% -3.64% 6.76% 12.02% 8.78% 2.10% 12.87%
EBIT Q/Q Growth		 -19.16% 2.03% -3.40% 16.90% -22.15% -3.96% 6.40% 11.18% 8.27% -0.67% 11.22%
NOPAT Q/Q Growth		 -18.20% 0.93% -6.70% 18.51% -21.96% -4.12% 5.75% 11.46% 8.95% -1.35% 11.45%
Net Income Q/Q Growth		 -19.93% 1.18% -8.13% 18.71% -36.80% 7.66% 5.02% 11.30% 11.44% -0.07% 5.47%
EPS Q/Q Growth		 -19.66% 1.43% -6.52% 23.81% -35.71% 11.84% 5.22% 13.39% 10.91% 6.12% 11.96%
Operating Cash Flow Q/Q Growth		 17.38% -12.24% 8.21% -29.67% 51.78% -45.80% -0.42% -74.81% 33.11% 22.81% 9.90%
Free Cash Flow Firm Q/Q Growth		 -0.92% -3.70% -1.53% 28.81% 15.46% 19.87% 10.44% 0.99% -29.61% -39.03% 3.86%
Invested Capital Q/Q Growth		 18.84% 51.26% -13.04% 171.21% -258.07% -54.75% -17.97% 113.23% 0.07% 617.89% -5.03%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -1,018.46% -1,137.79% 0.00% -403.58% -2,031.06% -1,607.32% -1,060.62% -722.54% -769.34% -778.47% -406.13%
Operating Margin		 -973.47% -1,093.29% 0.00% -394.00% -1,998.61% -1,588.96% -1,059.86% -726.57% -772.17% -808.86% -428.86%
EBIT Margin		 -982.23% -1,090.82% 0.00% -394.00% -2,001.60% -1,588.96% -1,052.57% -723.85% -775.01% -806.41% -428.67%
Profit (Net Income) Margin		 -909.82% -1,019.21% 0.00% -371.30% -2,112.62% -1,489.54% -1,001.23% -687.61% -710.81% -735.19% -416.15%
Tax Burden Percent		 99.05% 100.24% 103.63% 100.00% 99.86% 100.00% 100.73% 100.40% 99.60% 100.33% 100.04%
Interest Burden Percent		 93.52% 93.21% 94.28% 94.24% 105.70% 93.74% 94.43% 94.62% 92.08% 90.86% 97.04%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,843.90% 0.00% -18,644.79% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,840.60% 0.00% -18,642.06% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,815.10% 0.00% 18,603.99% 0.00%
Return on Equity (ROE)		 -45.68% -49.66% -42.10% -43.60% -49.02% -52.23% -54.00% -28.80% -56.95% -40.80% -53.48%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -3,484.04% 0.00% 0.00% 0.00% -4,558.00% -8,467.95% -1,225.15% -1,215.66%
Operating Return on Assets (OROA)		 -42.81% -48.51% 0.00% -15.48% -73.17% -56.66% -48.89% -29.38% -39.19% -44.21% -28.54%
Return on Assets (ROA)		 -39.66% -45.33% 0.00% -14.59% -77.23% -53.11% -46.51% -27.90% -35.95% -40.31% -27.70%
Return on Common Equity (ROCE)		 -45.68% -49.66% -42.10% -43.60% -49.02% -52.23% -54.00% -28.80% -56.95% -40.80% -53.48%
Return on Equity Simple (ROE_SIMPLE)		 -41.04% -44.58% 0.00% -46.86% -52.40% -54.26% 0.00% -67.43% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -93 -92 -98 -80 -97 -101 -96 -85 -77 -78 -69
NOPAT Margin		 -681.43% -765.30% 0.00% -275.80% -1,399.02% -1,112.27% -741.91% -508.60% -540.52% -566.20% -300.20%
Net Nonoperating Expense Percent (NNEP)		 -2.92% -3.08% -2.85% -2.45% -4.67% -3.36% -3.38% -3.31% -2.85% -2.73% -3.45%
Return On Investment Capital (ROIC_SIMPLE)		 - - -9.32% - - - -10.95% -10.84% -10.77% -10.43% -10.29%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 225.48% 245.19% 0.00% 107.45% 456.99% 334.77% 252.01% 174.46% 190.99% 221.39% 143.70%
R&D to Revenue		 847.99% 948.10% 0.00% 386.55% 1,641.61% 1,354.19% 907.85% 652.11% 681.19% 687.47% 385.16%
Operating Expenses to Revenue		 1,073.47% 1,193.29% 0.00% 494.00% 2,098.61% 1,688.96% 1,159.86% 826.57% 872.17% 908.86% 528.86%
Earnings before Interest and Taxes (EBIT)		 -134 -131 -135 -114 -139 -145 -136 -120 -110 -111 -99
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -138 -136 -139 -117 -141 -146 -137 -120 -110 -107 -93
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.25 2.70 2.60 2.38 2.22 2.17 1.36 0.94 1.36 2.48 1.55
Price to Tangible Book Value (P/TBV)		 3.25 2.70 2.60 2.38 2.22 2.17 1.36 0.94 1.36 2.48 1.55
Price to Revenue (P/Rev)		 67.77 54.05 75.27 46.83 46.97 48.45 20.52 16.15 18.38 32.23 15.39
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 122.02 0.00 0.00 0.00 0.00 57.89 35.17 13.04
Enterprise Value to Revenue (EV/Rev)		 46.37 33.73 45.87 27.36 25.44 25.44 4.86 0.00 4.94 19.78 5.92
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.07 -1.06 -1.05 -1.01 -1.02 -1.02 -1.03 -0.99 -1.01 -1.00 -1.00
Leverage Ratio		 1.23 1.25 1.23 1.20 1.21 1.21 1.30 1.24 1.24 1.23 1.32
Compound Leverage Factor		 1.15 1.17 1.16 1.13 1.28 1.13 1.22 1.17 1.14 1.11 1.28
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 8.86 6.90 5.25 5.14 3.94 3.75 -0.12 -0.93 -0.36 2.81 -0.35
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 9.41 9.72 8.67 9.03 7.21 6.73 5.77 4.90 5.19 6.21 5.08
Quick Ratio		 9.14 9.37 8.23 8.45 6.69 6.31 5.50 4.57 4.93 5.57 4.42
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -172 -178 -181 -129 -109 -87 -78 -77 -100 -139 -134
Operating Cash Flow to CapEx		 -2,100.05% -2,340.28% -6,121.97% -4,814.92% -5,749.60% -6,633.07% -8,684.51% -20,262.59% -41,682.85% -265,168.97% -54,988.10%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.04 0.04 0.03 0.04 0.04 0.04 0.05 0.04 0.05 0.05 0.07
Accounts Receivable Turnover		 13.41 9.85 1.80 2.55 5.29 5.62 2.57 1.94 4.46 5.78 7.53
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.80 1.71 1.20 1.65 1.45 1.38 1.92 1.59 1.99 2.34 3.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 27.22 37.07 202.37 143.40 69.02 65.00 141.81 187.95 81.77 63.14 48.50
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 27.22 37.07 202.37 143.40 69.02 65.00 141.81 187.95 81.77 63.14 48.50
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -30 -15 -17 12 -19 -29 -34 4.50 4.51 32 31
Invested Capital Turnover		 -0.76 -0.90 -0.63 -4.17 -1.89 -1.98 -2.29 5.59 -7.48 32.93 -40.79
Increase / (Decrease) in Invested Capital		 79 86 83 49 11 -14 -17 -7.29 23 61 65
Enterprise Value (EV)		 2,459 1,746 1,664 1,439 1,169 1,096 282 -39 261 1,138 401
Market Capitalization		 3,594 2,798 2,731 2,464 2,159 2,087 1,188 736 972 1,854 1,041
Book Value per Share		 $12.54 $11.72 $11.73 $10.85 $10.07 $9.48 $8.56 $7.53 $6.91 $6.97 $5.80
Tangible Book Value per Share		 $12.54 $11.72 $11.73 $10.85 $10.07 $9.48 $8.56 $7.53 $6.91 $6.97 $5.80
Total Capital		 1,105 1,037 1,050 1,036 971 963 872 780 715 748 671
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -1,135 -1,052 -1,067 -1,024 -990 -991 -906 -775 -711 -716 -641
Capital Expenditures (CapEx)		 4.30 4.33 1.52 2.51 1.01 1.28 0.98 0.74 0.24 0.03 0.13
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -68 -53 -29 -5.16 -39 -53 -73 -65 -59 -23 -26
Debt-free Net Working Capital (DFNWC)		 840 802 883 786 652 605 529 439 400 488 424
Net Working Capital (NWC)		 840 802 883 786 652 605 529 439 400 488 424
Net Nonoperating Expense (NNE)		 31 30 34 28 50 34 33 30 24 23 27
Net Nonoperating Obligations (NNO)		 -1,135 -1,052 -1,067 -1,024 -990 -991 -906 -775 -711 -716 -641
Total Depreciation and Amortization (D&A)		 -4.93 -5.63 -3.84 -2.77 -2.05 -1.67 -1.04 0.22 0.81 3.85 5.19
Debt-free, Cash-free Net Working Capital to Revenue		 -128.79% -102.86% -80.22% -9.81% -84.73% -122.77% -125.27% -142.53% -112.01% -39.68% -38.51%
Debt-free Net Working Capital to Revenue		 1,583.30% 1,548.42% 2,434.52% 1,494.43% 1,418.67% 1,404.68% 914.03% 962.93% 757.60% 848.66% 626.31%
Net Working Capital to Revenue		 1,583.30% 1,548.42% 2,434.52% 1,494.43% 1,418.67% 1,404.68% 914.03% 962.93% 757.60% 848.66% 626.31%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.40) ($1.38) ($1.47) ($1.12) ($1.52) ($1.34) ($1.27) ($1.10) ($0.98) ($0.92) ($0.81)
Adjusted Weighted Average Basic Shares Outstanding		 88.19M 88.65M 88.77M 95.50M 96.98M 101.00M 98.85M 103.50M 103.73M 110.19M 108.38M
Adjusted Diluted Earnings per Share		 ($1.40) ($1.38) ($1.47) ($1.12) ($1.52) ($1.34) ($1.27) ($1.10) ($0.98) ($0.92) ($0.81)
Adjusted Weighted Average Diluted Shares Outstanding		 88.19M 88.65M 88.77M 95.50M 96.98M 101.00M 98.85M 103.50M 103.73M 110.19M 108.38M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 88.49M 89.55M 96.11M 96.48M 101.58M 101.85M 103.52M 103.58M 107.35M 115.83M 118.13M
Normalized Net Operating Profit after Tax (NOPAT)		 -93 -92 -98 -80 -97 -101 -96 -85 -77 -78 -69
Normalized NOPAT Margin		 -681.43% -765.30% 0.00% -275.80% -1,399.02% -1,112.27% -741.91% -508.60% -540.52% -566.20% -300.20%
Pre Tax Income Margin		 -918.57% -1,016.74% 0.00% -371.30% -2,115.61% -1,489.54% -993.93% -684.89% -713.65% -732.75% -415.97%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Intellia Therapeutics (NTLA) — here are concise, data-driven takeaways from the last four years of quarterly statements, focused on Revenue, Cash, and the company’s burn through R&D and operating costs. Items are sorted with positive impacts first, then neutral, then negative.

  • Q4 2025 Revenue rose to $23.02 million, up from $12.87 million in Q4 2024.
  • Cash and cash equivalents stood at $193.39 million in Q3 2025, marking a meaningful liquidity improvement from earlier quarters.
  • In Q3 2025, net cash from continuing financing activities produced a sizable inflow of $114.86 million, aided by equity issuance.
  • In Q2 2025, net cash from continuing investing activities totaled $106.91 million, reflecting proceeds from the sale/maturity of investments.
  • R&D expense remained a major cash outflow in Q4 2025, at $88.65 million, underscoring ongoing development burn.
  • Retained earnings on the balance sheet show a large accumulated deficit (approximately -$2.39 billion) as of Q3 2025.
  • Weighted average shares outstanding for 2025 range around 108–118 million, indicating ongoing dilution dynamics.
  • Net income attributable to common shareholders in Q4 2025 is -$95.79 million, continuing annual losses.
  • Net cash from continuing operating activities in Q4 2025 is -$69.29 million, signaling ongoing cash burn from core operations.
  • Total operating expenses in Q4 2025 were $121.73 million, far exceeding revenue and contributing to the quarterly loss.
05/09/26 11:08 AM ETAI Generated. May Contain Errors.

Intellia Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Intellia Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Intellia Therapeutics' net income appears to be on an upward trend, with a most recent value of -$412.69 million in 2025, rising from -$12.40 million in 2015. The previous period was -$519.02 million in 2024. Find out what analysts predict for Intellia Therapeutics in the coming months.

Intellia Therapeutics' total operating income in 2025 was -$440.99 million, based on the following breakdown:
  • Total Gross Profit: $67.67 million
  • Total Operating Expenses: $508.66 million

Over the last 10 years, Intellia Therapeutics' total revenue changed from $6.04 million in 2015 to $67.67 million in 2025, a change of 1,019.6%.

Intellia Therapeutics' total liabilities were at $170.73 million at the end of 2025, a 46.5% decrease from 2024, and a 1,054.9% increase since 2015.

In the past 10 years, Intellia Therapeutics' cash and equivalents has ranged from $57.23 million in 2019 to $523.51 million in 2022, and is currently $155.46 million as of their latest financial filing in 2025.

Over the last 10 years, Intellia Therapeutics' book value per share changed from -87.25 in 2015 to 5.80 in 2025, a change of -106.6%.


Related Companies

Financial statements for NASDAQ:NTLA last updated on 3/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel